2006
DOI: 10.1007/978-1-4020-5133-3_17
|View full text |Cite
|
Sign up to set email alerts
|

Methylation Patterns and Chemosensitivity in NSCLC

Abstract: Survival in advanced non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy is rather variable. Methylation-dependent transcriptional silencing of 14-3-3sigma, a major G2/M checkpoint control gene, could be a predictor of longer survival. A sensitive methylation-specific polymerase chain reaction assay was used to evaluate 14-3-3sigma methylation status in pretreatment serum DNA obtained from 115 cisplatin-plus-gemcitabine-treated advanced NSCLC patients. 14-3-3sigma methylation w… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2008
2008
2015
2015

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 37 publications
0
1
0
Order By: Relevance
“…Methylation of this major G2/M checkpoint control gene was observed in all histologic types of 39 NSCLC patients. Median survival was significantly longer in the methylation-positive patient group than its counterpart [28]. Using the methyLight analysis, DNA methylation of RASSF1A (ras association domain family 1A) was investigated in pretherapeutic serum samples collected 1 year after surgery from 148 patients with breast cancer who were receiving adjuvant tamoxifen.…”
mentioning
confidence: 99%
“…Methylation of this major G2/M checkpoint control gene was observed in all histologic types of 39 NSCLC patients. Median survival was significantly longer in the methylation-positive patient group than its counterpart [28]. Using the methyLight analysis, DNA methylation of RASSF1A (ras association domain family 1A) was investigated in pretherapeutic serum samples collected 1 year after surgery from 148 patients with breast cancer who were receiving adjuvant tamoxifen.…”
mentioning
confidence: 99%